Lucentis in Advanced Macular Degeneration
NCT00896779
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Macular Degeneration
Interventions
DRUG:
ranibizumab
Sponsor
Steven R. Sanislo
Collaborators
[object Object]
[object Object]
[object Object]